Emerging IgAN Therapies Bring Hope – But Patients Still Face Emotional and Financial Barriers, According to Spherix Global Insights
IgAN research, focusing on real-world patient experiences, reveals unmet needs in disease education, affordability, and care navigationEXTON, PA, April 08, 2025 (GLOBE NEWSWIRE) -- Spherix Global ...
Rheumatology Advisor4h
Vanrafia Gets Accelerated Approval for Immunoglobulin A Nephropathy
The FDA has granted accelerated approval to Vanrafia to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression.
CareMed Has Been Selected as a National Specialty Pharmacy Partner for VANRAFIA™ (atrasentan)
CareMed, an independent specialty pharmacy, is in the Limited Distribution Network for Vanrafia™ (atrasentan), for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy ...
PharmiWeb8h
European Commission Approves Expanded Label for KAFTRIO® in Combination With Ivacaftor for People With Cystic Fibrosis
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted regulatory approval for a label expansion of KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in a combination ...
XOMA Royalty Corporation's Preferreds Still Offer Attractive Yields With A Biotech Twist
XOMA's preferred shares (XOMAO, XOMAP) offer secure, attractive yields backed by biotech royalties, FDA-approved assets, and ...
Managed Healthcare Executive1h
Bkemv and Epysqli, Two Biosimilars of Soliris, are Now Available
Bkemv is being offered at 10% off Soliris, and Epysqli is offered at 30% below Soliris. Both biosimilars treat several of the ...
Managed Healthcare Executive21h
FDA Approves Uplizna for Chronic Inflammatory Condition IgG4-RD
Uplizna is the first approved treatment for immunoglobulin G4-related disease (IgG4-RD), a chronic inflammatory condition ...